Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):135-44.

Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy?

Author information

1
Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267-0559, USA.

Abstract

Two primary hypotheses have been proposed to explain the pathophysiology of the neuroleptic malignant syndrome (NMS): 1) that NMS is produced by abrupt and extensive central dopamine receptor blockade by neuroleptics, particularly in nigrostriatal and hypothalamic pathways; and 2) that NMS, like malignant hyperthermia (MH), results from a preexisting defect in skeletal muscle metabolism that is unmasked or provoked by neuroleptic exposure. To evaluate these models, the authors review studies published since 1980 of the clinical features, epidemiology, risk factors, laboratory assessment, and relevant animal models of NMS and MH. Data from these studies suggest that although NMS and MH are clinically similar, they are pharmacologically distinct, implying that cross-reactivity between triggering agents is unlikely to occur.

PMID:
7626956
DOI:
10.1176/jnp.7.2.135
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center